Baseline and on-treatment plasma-based genomics as a predictor of outcome in SAVANNAH: Savolitinib plus osimertinib in EGFRm MET overexpressed/amplified NSCLC post-osimertinib

被引：1
|
作者：
Hartmaier, Ryan James
Markovets, Aleksandra
Xu, Wanning
Baczynska, Agata
Todd, Alexander
Ahn, Myung-Ju
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-LB294
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB294
引用
收藏
页数：3
相关论文
共 8 条
  • [1] MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib plus osimertinib in EGFRm NSCLC Post-Osimertinib
    Ahn, M-J.
    De Marinis, F.
    Bonanno, L.
    Cho, B. C.
    Kim, T. -M.
    Cheng, S.
    Novello, S.
    Proto, C.
    Kim, S. -W.
    Lee, J. S.
    Metro, G.
    Yang, J. C.
    Xu, W.
    Hartmaier, R.
    Telaranta-Keerie, A.
    Poole, L.
    Sequist, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S469 - S470
  • [2] SAFFRON: Savolitinib plus Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib
    Lindsay, Colin
    Xu, Wanning
    Telaranta-Keerie, Aino
    Jia, Nan
    Hartmaier, Ryan J.
    Lu, Shun
    [J]. LUNG CANCER, 2024, 190
  • [3] SAFFRON: Savolitinib plus Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib
    Piotrowska, Zofia
    Xu, Wanning
    Telaranta-Keerie, Aino
    Jia, Nan
    Hartmaier, Ryan
    Lu, Shun
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E25 - E26
  • [4] SAFFRON: Ph3 Savolitinib plus Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib
    Lu, S.
    Xu, W.
    Telaranta-Keerie, A.
    Jia, N.
    Hartmaier, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S468 - S469
  • [5] Osimertinib plus Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis
    Han, J.
    Sequist, L.
    Ahn, M.
    Cho, B. C.
    Yu, H.
    Kim, S.
    Yang, J. C.
    Lee, J. S.
    Su, W.
    Kowalski, D. M.
    Orlov, S.
    Cantarini, M.
    Ren, S.
    Frewer, P.
    Ou, X.
    Janne, P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S227 - S228
  • [6] The effect of savolitinib plus osimertinib on ctDNA clearance in patients with EGFR mutation positive (EGFRm) MET-amplified NSCLC in the TATTON study
    Hartmaier, Ryan
    Han, Ji-Youn
    Ahn, Myung-Ju
    Cho, Byoung Chul
    Cantarini, Mireille
    Frewer, Paul
    Frigault, Melanie M.
    Oxnard, Geoffrey
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [7] Savolitinib (savo) plus osimertinib (osi) vs savo plus placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi
    Yang, James Chih-Hsin
    Chen, Yuh-Min
    Batra, Ullas
    Do, Kien
    Sitthideatphaiboon, Piyada
    Danchaivijitr, Pongwut
    Lee, Kang-Yun
    Chindaprasirt, Jarin
    Yang, Cheng-Ta
    Chang, Gee-Chen
    Charoentum, Chaiyut
    Ungtrakul, Teerapat
    Moran, Juan Ignacio Hernandez
    Hartmaier, Ryan
    Haskins, Matthew
    Xu, Wanning
    Riess, Jonathan W.
    [J]. CANCER RESEARCH, 2024, 84 (07)
  • [8] FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed
    Janne, Pasi A.
    Kobayashi, Kunihiko
    Robichaux, Jacqulyne
    Lee, Chee Khoon
    Sugawara, Shunichi
    Yang, Tsung-Ying
    Kim, Tae Min
    Yanagitani, Noriko
    Kim, Sang-We
    Markovets, Aleksandra
    Bhetariya, Preetida
    Poole, Lynne
    Ghiorghiu, Dana
    Hartmaier, Ryan
    Yang, James Chih-Hsin
    Planchard, David
    [J]. CANCER RESEARCH, 2024, 84 (07)
1